CN100525753C - 辅酶q10亚微乳注射液及制备方法 - Google Patents
辅酶q10亚微乳注射液及制备方法 Download PDFInfo
- Publication number
- CN100525753C CN100525753C CNB2005100477153A CN200510047715A CN100525753C CN 100525753 C CN100525753 C CN 100525753C CN B2005100477153 A CNB2005100477153 A CN B2005100477153A CN 200510047715 A CN200510047715 A CN 200510047715A CN 100525753 C CN100525753 C CN 100525753C
- Authority
- CN
- China
- Prior art keywords
- ubiquinone
- injection
- water
- sub
- lecithin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 title claims abstract description 114
- 235000017471 coenzyme Q10 Nutrition 0.000 title claims abstract description 103
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 title claims abstract description 102
- 238000002347 injection Methods 0.000 title claims abstract description 72
- 239000007924 injection Substances 0.000 title claims abstract description 72
- 239000000839 emulsion Substances 0.000 title claims abstract description 27
- 238000002360 preparation method Methods 0.000 title claims description 21
- 239000007788 liquid Substances 0.000 title description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 71
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 47
- 239000004530 micro-emulsion Substances 0.000 claims abstract description 41
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract description 30
- 235000010445 lecithin Nutrition 0.000 claims abstract description 30
- 239000000787 lecithin Substances 0.000 claims abstract description 30
- 229940067606 lecithin Drugs 0.000 claims abstract description 30
- 235000012424 soybean oil Nutrition 0.000 claims abstract description 25
- 238000000034 method Methods 0.000 claims abstract description 22
- 235000019198 oils Nutrition 0.000 claims abstract description 10
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 claims description 97
- 229940035936 ubiquinone Drugs 0.000 claims description 96
- 239000008215 water for injection Substances 0.000 claims description 27
- 239000003549 soybean oil Substances 0.000 claims description 24
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 15
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 15
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 15
- 239000005642 Oleic acid Substances 0.000 claims description 15
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 15
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 15
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 15
- 230000001954 sterilising effect Effects 0.000 claims description 15
- 210000003022 colostrum Anatomy 0.000 claims description 13
- 235000021277 colostrum Nutrition 0.000 claims description 13
- 238000004659 sterilization and disinfection Methods 0.000 claims description 13
- 238000000265 homogenisation Methods 0.000 claims description 12
- 239000002994 raw material Substances 0.000 claims description 12
- 238000001914 filtration Methods 0.000 claims description 9
- 239000003921 oil Substances 0.000 claims description 9
- 230000004087 circulation Effects 0.000 claims description 8
- 239000012982 microporous membrane Substances 0.000 claims description 6
- 238000012856 packing Methods 0.000 claims description 5
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 5
- 239000008158 vegetable oil Substances 0.000 claims description 5
- 102000002322 Egg Proteins Human genes 0.000 claims description 4
- 108010000912 Egg Proteins Proteins 0.000 claims description 4
- 241000287828 Gallus gallus Species 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 4
- 230000010355 oscillation Effects 0.000 claims description 4
- 210000004681 ovum Anatomy 0.000 claims description 4
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 3
- 235000019484 Rapeseed oil Nutrition 0.000 claims description 3
- 238000004140 cleaning Methods 0.000 claims description 3
- 229940083466 soybean lecithin Drugs 0.000 claims description 3
- 238000007731 hot pressing Methods 0.000 claims description 2
- 238000011085 pressure filtration Methods 0.000 claims description 2
- 235000011187 glycerol Nutrition 0.000 abstract description 19
- 239000003795 chemical substances by application Substances 0.000 abstract description 6
- 238000006243 chemical reaction Methods 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 4
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 2
- 239000005515 coenzyme Substances 0.000 abstract description 2
- 208000006454 hepatitis Diseases 0.000 abstract description 2
- 231100000283 hepatitis Toxicity 0.000 abstract description 2
- 229940110767 coenzyme Q10 Drugs 0.000 abstract 3
- 239000002245 particle Substances 0.000 description 13
- 239000003814 drug Substances 0.000 description 12
- 238000005516 engineering process Methods 0.000 description 11
- 238000012360 testing method Methods 0.000 description 9
- 241000196324 Embryophyta Species 0.000 description 8
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 7
- 210000002969 egg yolk Anatomy 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 210000000481 breast Anatomy 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 206010018910 Haemolysis Diseases 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000008588 hemolysis Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 208000033065 inborn errors of immunity Diseases 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 1
- 101100007300 Caenorhabditis elegans coq-2 gene Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 235000020603 homogenised milk Nutrition 0.000 description 1
- 210000004276 hyalin Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 238000002356 laser light scattering Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 230000008811 mitochondrial respiratory chain Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 208000001297 phlebitis Diseases 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007962 solid dispersion Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 229960004747 ubidecarenone Drugs 0.000 description 1
- 229940040064 ubiquinol Drugs 0.000 description 1
- QNTNKSLOFHEFPK-UPTCCGCDSA-N ubiquinol-10 Chemical compound COC1=C(O)C(C)=C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)C(O)=C1OC QNTNKSLOFHEFPK-UPTCCGCDSA-N 0.000 description 1
- 229940045042 ubiquinone q2 Drugs 0.000 description 1
- SQQWBSBBCSFQGC-JLHYYAGUSA-N ubiquinone-2 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CCC=C(C)C)=C(C)C1=O SQQWBSBBCSFQGC-JLHYYAGUSA-N 0.000 description 1
- 150000003669 ubiquinones Chemical class 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100477153A CN100525753C (zh) | 2005-11-15 | 2005-11-15 | 辅酶q10亚微乳注射液及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100477153A CN100525753C (zh) | 2005-11-15 | 2005-11-15 | 辅酶q10亚微乳注射液及制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1965805A CN1965805A (zh) | 2007-05-23 |
CN100525753C true CN100525753C (zh) | 2009-08-12 |
Family
ID=38074898
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005100477153A Active CN100525753C (zh) | 2005-11-15 | 2005-11-15 | 辅酶q10亚微乳注射液及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100525753C (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101381747B (zh) * | 2008-10-28 | 2012-07-04 | 中国人民解放军军事医学科学院野战输血研究所 | 一种从微生物中提取辅酶q10的方法 |
CN101721373B (zh) * | 2009-11-12 | 2012-09-05 | 王明 | 一种头孢地尼亚微乳固体制剂及其应用 |
CN114588109B (zh) * | 2020-12-07 | 2023-09-12 | 沈阳药科大学 | 辅酶q10乳剂及其制备方法和用途 |
WO2022192633A1 (en) * | 2021-03-11 | 2022-09-15 | The Trustees Of Columbia University In The City Of New York | A pharmaceutical composition comprising ubiquinone-5 and method of use thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1331606A (zh) * | 1998-12-21 | 2002-01-16 | 弗雷泽纽斯卡比奥地利有限公司 | 表现抗过氧化作用对人器官引起的损伤的保护作用的水包油乳液及其生产和应用 |
CN1501903A (zh) * | 2001-05-09 | 2004-06-02 | ��Ԩ��ѧ��ҵ��ʽ���� | 还原型辅酶q的稳定溶液 |
CN1520805A (zh) * | 2003-01-30 | 2004-08-18 | 日清药业股份有限公司 | 含有泛醌的组合物 |
CN1555257A (zh) * | 2001-07-17 | 2004-12-15 | ������������ʽ���� | 家禽腹水预防剂 |
CN1559387A (zh) * | 2004-03-10 | 2005-01-05 | 红 刘 | 辅酶q10静脉输注注射液及其制备方法 |
-
2005
- 2005-11-15 CN CNB2005100477153A patent/CN100525753C/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1331606A (zh) * | 1998-12-21 | 2002-01-16 | 弗雷泽纽斯卡比奥地利有限公司 | 表现抗过氧化作用对人器官引起的损伤的保护作用的水包油乳液及其生产和应用 |
CN1501903A (zh) * | 2001-05-09 | 2004-06-02 | ��Ԩ��ѧ��ҵ��ʽ���� | 还原型辅酶q的稳定溶液 |
CN1555257A (zh) * | 2001-07-17 | 2004-12-15 | ������������ʽ���� | 家禽腹水预防剂 |
CN1520805A (zh) * | 2003-01-30 | 2004-08-18 | 日清药业股份有限公司 | 含有泛醌的组合物 |
CN1559387A (zh) * | 2004-03-10 | 2005-01-05 | 红 刘 | 辅酶q10静脉输注注射液及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN1965805A (zh) | 2007-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009012718A1 (fr) | Émulsifiant composite, émulsion préparée à partir de celui-ci et procédé de préparation de celle-ci | |
CN102159187B (zh) | 长春花生物碱纳米乳剂注射液及其制备方法 | |
CN104224711B (zh) | 以类固醇复合物为中间载体的紫杉醇亚微乳 | |
CN109310643A (zh) | 含甘油脂肪酸酯衍生物或丙二醇脂肪酸酯衍生物的度他雄胺和他达拉非复合制剂及包含其的口服胶囊制剂 | |
RU2716218C2 (ru) | Состав для инъекции на основе жировой эмульсии кабазитаксела, способ его получения и применение | |
US20230398072A1 (en) | Concentrate containing poorly soluble drug and emulsion prepared therefrom | |
CN103110579A (zh) | 前列地尔注射剂 | |
CN101496787A (zh) | 一种荷电性的前列腺素e1脂微球注射液及其制备方法 | |
CN109223712B (zh) | 氟比洛芬酯注射用乳剂及其制备方法 | |
CN100525753C (zh) | 辅酶q10亚微乳注射液及制备方法 | |
CN101006997B (zh) | 复方紫杉醇及衍生物多西他赛脂肪乳剂和制备方法 | |
WO2011120339A1 (zh) | 牛蒡苷元的微乳制剂 | |
CN102552134B (zh) | 含有维生素k1的脂肪乳剂 | |
KR100211772B1 (ko) | 활성물질을 함유하는 동결건조 유제 | |
CN101143142A (zh) | 水飞蓟宾过饱和自微乳组合物及其制备方法 | |
CN101416963A (zh) | 注射用尼莫地平冻干亚微乳剂及其制备方法 | |
CN102058531B (zh) | 一种脑保护治疗药物脂肪乳剂的制备 | |
CN107007569A (zh) | 一种载槲皮素和白藜芦醇的磁性脂质纳米粒及其制备方法 | |
CN114010597B (zh) | 一种特殊油脂比例的棓丙酯脂肪乳注射液及其制备方法 | |
CN109758423A (zh) | 使用维生素k1脂肪乳注射液治疗凝血功能障碍的方法 | |
CN115554241A (zh) | 一种胶束型维生素k1注射液及其制备方法和应用 | |
CN100362993C (zh) | 一种丹参酮乳剂及其制备方法 | |
CN104546718B (zh) | 一种长循环雷贝拉唑脂质体组合物及其制备方法和应用 | |
CN101422454B (zh) | ω-3多不饱和脂肪酸丹参酮ⅡA亚微乳及其制备方法 | |
CN102144969B (zh) | 一种依托泊苷纳米混悬液冻干制剂的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: SHENYANG WANJIA BIOTECHNOLOGY RESEARCH INSTITUTE C Free format text: FORMER OWNER: DONG YINGJIE Effective date: 20100716 Owner name: LIAONING WANJIA MEDICAL TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: SHENYANG WANJIA BIOTECHNOLOGY RESEARCH INSTITUTE CO., LTD. Effective date: 20100716 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 110015 NO.88, FENGLE STREET 1, DONGLING DISTRICT, SHENYANG CITY, LIAONING PROVINCE TO: 110015 NO.88, FENGLE STREET 1, SHENHE DISTRICT, SHENYANG CITY, LIAONING PROVINCE Free format text: CORRECT: ADDRESS; FROM: 110015 NO.88, FENGLE STREET 1, SHENHE DISTRICT, SHENYANG CITY, LIAONING PROVINCE TO: 117000 BIOMEDICAL INDUSTRIAL PARK, ECONOMIC DEVELOPMENT ZONE, XIHU DISTRICT, BENXI CITY, LIAONING PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20100716 Address after: 117000 bio pharmaceutical industry park, economic development zone, Benxi, Liaoning Patentee after: LIAONING WANJIA MEDICAL TECHNOLOGY Co.,Ltd. Address before: Fengle Shenhe District of Shenyang city in Liaoning province 110015 Street No. 88 Patentee before: Shenyang Wanjia Institute of Biotechnology Co.,Ltd. Effective date of registration: 20100716 Address after: Fengle Shenhe District of Shenyang city in Liaoning province 110015 Street No. 88 Patentee after: Shenyang Wanjia Institute of Biotechnology Co.,Ltd. Address before: 110015 Liaoning Province in Dongling District of Shenyang City fengle Street No. 88 Patentee before: Dong Yingjie |
|
TR01 | Transfer of patent right |
Effective date of registration: 20190731 Address after: Fengle Shenhe District of Shenyang city in Liaoning province 110015 Street No. 88 Co-patentee after: Suqian Medical Technology Co.,Ltd. Patentee after: LIAONING WANJIA MEDICAL TECHNOLOGY Co.,Ltd. Address before: 117000 bio pharmaceutical industry park, economic development zone, Benxi, Liaoning Patentee before: LIAONING WANJIA MEDICAL TECHNOLOGY Co.,Ltd. |
|
TR01 | Transfer of patent right |